Abstract:
Objective To analyze and compare the clinical efficacy and safety of mFOLFOX6 and FOLFOX4 chemotherapy regimens in the treatment of rectal cancer patients.
Methods A total of 118 patients with rectal cancer who were admitted to Xuancheng Central Hospital from January 1, 2020 to August 31, 2022 were selected, and were divided into mFOLFOX6 group(n=59)and FOLFOX4 group(n=59)using random alphabet method.The patients were treated with mFOLFOX6 and FOLFOX4 chemotherapy regimens, respectively.The efficacy and incidence of adverse reactions were compared between the two groups.
Results There were no significant differences in objective response rate and disease control rate between the mFOLFOX6 group and FOLFOX4 group(P>0.05). The results of flow cytometry showed that there was no significant difference in CD3+ cell subset between the mFOLFOX6 group and FOLFOX4 group after treatment(P>0.05), while CD4+ cell subset and CD4+ /CD8+ ratio in the mFOLFOX6 group were significantly higher than those in the FOLFOX4 group(P<0.05). In terms of quality of life, global health status was improved in both mFOLFOX6 and FOLFOX4 groups after treatment(P<0.05). The scores of functional scale and overall quality of life in the mFOLFOX6 group were significantly higher than those in the FOLFOX4 group, while the score of symptom scale was significantly lower than that in the FOLFOX4 group(P<0.05). The incidences of adverse reactions including nausea and vomiting, diarrhea and peripheral neurotoxicity were similar between the two groups(P>0.05). The incidence ofⅢ-Ⅳleukopenia in the mFOLFOX6 group was slightly higher than that in the FOLFOX4 group, but there was no statistically significant difference(P>0.05). The incidence of liver function damage in the mFOLFOX6 group was significantly higher than that in the FOLFOX4 group, and there was a statistically significant difference(P<0.05).
Conclusion Both mFOLFOX6 and FOLFOX4 regimen can play a good role in the treatment of rectal cancer, and mFOLFOX6 regimen can improve the quality of life and immune function of patients, but the incidence of liver damage is high, and patients with liver insufficiency should be used carefully.
Key words:
Rectal cancer,
Clinical efficacy,
Adverse reactions,
mFOLFOX6,
FOLFOX4
Jun Dong, Fangfang Wu. Clinical efficacy and safety analysis of mFOLFOX6 and FOLFOX4 chemotherapy regimens in the treatment of rectal cancer[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 236-240.